title: Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
abstract: The purpose of this study was to evaluate associations between hormonal therapy for breast cancer and subsequent diabetes incidence.
  
  
  
  The Surveillance, Epidemiology and End Results-Medicare linked data were used. Stage I-III breast cancer patients 65 years or older who filled at least two prescriptions for an aromatase inhibitor (AI) or tamoxifen by the end of 2008, and within 12 months of breast cancer diagnosis, were selected. Women without cancer from a 5% random sample of Medicare beneficiaries were frequency matched to patients by age group, and new onset diabetes was monitored for 24 months postbaseline in both groups of women.
  
  
  
  Cox-proportional hazards analysis failed to show an association between AI use and subsequent diabetes onset after adjusting for age, race, and comorbidity (hazard ratio: 0.99; 95% confidence interval: 0.84-1.18). This study also failed to show an association between tamoxifen use and diabetes onset (hazard ratio: 0.79; 95% confidence interval: 0.54-1.17).
  
  
  
  Study findings provide evidence that postmenopausal AI and tamoxifen users do not experience an increased risk of diabetes in the 2 years after treatment initiation. Whether these findings will hold with longer duration follow-up deserves a closer look.
authors.affiliation: Department of Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, 683 Hoes Lane West, Piscataway. Electronic address: veziname@sph.rutgers.edu.
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Santorelli
authors.affiliation: Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick; Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 125 Paterson Street, New Brunswick.
authors.forename: Kim M
authors.initials: KM
authors.lastname: Hirshfield
authors.affiliation: Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 125 Paterson Street, New Brunswick.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Steinberg
authors.affiliation: Department of Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, 683 Hoes Lane West, Piscataway.
authors.forename: George G
authors.initials: GG
authors.lastname: Rhoads
authors.affiliation: Department of Biostatistics, School of Public Health, Rutgers, The State University of New Jersey, 683 Hoes Lane West, Piscataway.
authors.forename: Yong
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Department of Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, 683 Hoes Lane West, Piscataway; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick.
authors.forename: Kitaw
authors.initials: K
authors.lastname: Demissie
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000601:surgery; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000453:epidemiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D015994:Incidence; D017698:Postmenopause; D018570:Risk Assessment; D018426:SEER Program; D016019:Survival Analysis; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen
keywords: Aromatase inhibitors; Breast neoplasms; Diabetes mellitus; Postmenopause; Tamoxifen